In Myelodysplastic syndrome, hypomethylating agents, 5-azacytidine and 5-aza-2'-deoxycytidine (decitabine), which work by inhibiting DNA methyltransferase, have been approved (MDS). Cytopenias, nausea, pain, and local reactions...